{"id":"W2321989483","doi":"10.17925/ee.2016.12.01.31","title":"Cardiovascular Outcomes with Empagliflozin – News for Type 2 Diabetes Therapy","year":2016,"lang":"en","type":"editorial","venue":"touchREVIEWS in Endocrinology","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"Novo Nordisk; Sanofi; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Empagliflozin; Medicine; Type 2 diabetes; Clinical endpoint; Diabetes mellitus; Incidence (geometry); Endpoint Determination; Internal medicine; Pharmacology; Clinical trial; Endocrinology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005222634,0.002388287,0.002500608,0.001660203,0.001024702,0.004052511,0.001812368,0.006643054,0.008073206],"category_scores_gemma":[0.01267815,0.0007183101,0.002062371,0.0009357758,0.001162138,0.002938836,0.001103875,0.01565211,0.00552592],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001519347,"about_ca_system_score_gemma":0.001470897,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006615127,"about_ca_topic_score_gemma":0.001514978,"domain_scores_codex":[0.9976074,0.0004878193,0.0004510163,0.0002440317,0.001087548,0.0001222845],"domain_scores_gemma":[0.9912989,0.004079924,0.0006893732,0.0002793987,0.002855498,0.0007968587],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00008934754,0.00002810909,0.00004378604,0.000653232,0.00005577577,0.00008014304,0.00001443046,0.00002840035,0.0001321966,0.0003539656,0.9728415,0.02567914],"study_design_scores_gemma":[0.0001739495,0.00008111932,0.0006099344,0.001418773,0.000152256,0.0002253218,0.00003069115,0.0001478051,0.0001686895,0.001237259,0.9957278,0.00002648073],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"editorial","genre_gemma":"editorial","genre_scores_codex":[0.00009545955,0.05503993,0.0001303533,0.04631159,0.8969008,0.0000216498,0.00006007006,0.00006626613,0.001373937],"genre_scores_gemma":[0.0005472084,0.04221169,0.0001514442,0.02747688,0.924352,0.00002438544,0.00005242098,0.00003521739,0.00514882],"genre_candidate":"editorial","genre_consensus":"editorial","teacher_disagreement_score":0.008073206,"threshold_uncertainty_score":0.02762026,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03218821642641539,"score_gpt":0.3249771707485819,"score_spread":0.2927889543221665,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}